[1] Van Ingen J, Bendien SA, de Lange WC,et al. Clinical relevance of non-tuberculous mycobacteria isolated in the Nijmegen-Arnhem region, the Netherlands[J].Thorax, 2009, 64(6):502-506.
[2] Lai CC, Tan CK, Chou CH, et al. Increasing incidence of nontuberculous mycobacteria , Taiwan, 2000-2008[J]. Emerg Infect Dis, 2010,16(2):294-296.
[3] Andréjak C, Thomsen VØ, Johansen IS, et al. Nontuberculous pulmonary mycobacteriosis in Denmark: incidence and prognostic factors[J]. Am J Respir Crit Care Med, 2010,181(5):514-521.
[4] 全国结核病流行病学抽样调查技术指导组.第四次全国结核病流行病学抽样调查报告[J].中华结核和呼吸杂志,2002,25(1):3-7.
[5] 马 玙,黄海荣.浅谈非结核分枝杆菌肺病的诊断[J].中华结核和呼吸杂志,2012,35(8):564-566.
[6] 赵建宏,李雅静,温海楠,等. 非结核分枝杆菌感染的分子诊断研究进展[J].检验医学,2012,27(3):155-158.
[7] 赵立平,于 霞,姜广路,等.对BACTETM MGIT960培养报告结果为阴性的培养管中颗粒性物质的研究[J].中国防痨杂志,2013,35(1):27-31.
[8] Heginbothom ML. The relationship between the in vitro drug susceptibility of opportunist mycobacteria and their in vivo response to treatment[J]. Int J Tuberc Lung Dis,2001,5(6):539-545.
[9] Van Ingen J, van der Laan T, Dekhuijzen R,et al. In vitro drug susceptibility of 2 275 clinical non-tuberculous Mycobacterium isolates of 49 species in the Netherlands[J]. Int J Antimicrob Agents,2010,35(2):169-173.
[10] Giampaglia CM, Martins MC, Chimara E, et al.Differentiation of Mycobacterium tuberculosis from other mycobacteria with rho-nitrobenzoic acid using MGIT960[J]. Int J Tuberc Lung Dis,2007,11(7):803-807.
[11] 刘 冠,宋媛媛,姜广路,等.SMIS检测分枝菌酸在分枝杆菌菌种鉴定中的作用[J].中华检验医学杂志,2011,34(2):105-110.
[12] 马 玙.关注非结核分枝杆菌肺病的诊断和治疗[J].中华结核和呼吸杂志,2011,34(8):566-568.
[13] 唐神结,沙 巍,肖和平,等. 非结核分枝杆菌病的研究进展[J]. 中华结核和呼吸杂志,2012,35(7):527-531. |